Antidepressant Drug Adverse Reaction, Depression
Conditions
Keywords
depression, pharmacogenomics, antidepressant response, biological markers, clinical variables
Brief summary
The Purpose of this study is to predict antidepressant response in advance using pharmacogenomics and peripheral biological markers in depressed patients.
Detailed description
The difficulties to treat depressed patients are 1)the patients don't respond to antidepressant is about 40% of which, and 2) The time lag is existed until the patients respond to antidepressant and show the treatment effects. If it is predicted the response of antidepressant in advance, it would be overcome such problems. Drug response generally is known to be related to the individual genetic information and the environmental factors. We are going to investigation about antidepressant response using these approaches.
Interventions
Antidepressant administration of SSRI class for 6 weeks under therapeutic dose
Antidepressant administration of non-SSRI class for 6 weeks under therapeutic dose
Sponsors
Samsung Medical Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
25 Years to 85 Years
Healthy volunteers
Yes
Inclusion criteria
1. 25 \< age \<85 2. major depressed patients satisfied with the diagnosis criteria depression of DSM-IV 3. interview with one more patient's family member for objective diagnosis and final diagnosis decision by agreements of two more psychiatric physicians
Exclusion criteria
1. received psychotropic medication within 2 weeks of the study or fluoxetine within 4 weeks 2. potential study participants for pregnancy, significant medical conditions, abnormal laboratory baseline values, unstable psychiatric features(eg.suicidal), history of alcohol of drug dependence, seizures, head trauma with loss of consciousness, neurological illness, or concomitant Axis I psychiatric disorder.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| all pharmacogenetic and biological marker variables cause drug response | 24weeks |
Secondary
| Measure | Time frame |
|---|---|
| all clinical cause drug response | 24weeks |
Countries
South Korea
Contacts
Primary ContactDoh Kwan Kim, M.D.,Ph.D
Backup ContactShinn-Won Lim, phD
Outcome results
None listed